Open Access

C‑type natriuretic peptide prevents angiotensin II‑induced atrial connexin 40 and 43 dysregulation by activating AMP‑activated kinase signaling

  • Authors:
    • Da‑Zhi Ding
    • Ya‑Nan Jia
    • Bo Zhang
    • Cheng‑Ming Guan
    • Shuai Zhou
    • Xiang Li
    • Xun Cui
  • View Affiliations

  • Published online on: October 15, 2019     https://doi.org/10.3892/mmr.2019.10744
  • Pages: 5091-5099
  • Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

C‑type natriuretic peptide (CNP), from the family of natriuretic peptides (NPs), has been shown to induce antihypertrophic and antifibrotic effects in cardiomyocytes. However, the roles of CNP in the atrial dysregulation of connexin (Cx)40 and Cx43 remain to be elucidated. The present study aimed to investigate the effects of CNP on angiotensin (Ang) II‑induced Cx40 and Cx43 dysregulation in isolated perfused beating rat left atria. A rat isolated perfused beating atrial model was used and the protein levels were determined via western blotting. Ang II significantly upregulated NF‑κB, activator protein‑1, transforming growth factor‑β1 (TGF‑β1), collagen I and matrix metalloproteinase 2, leading to atrial fibrosis, and downregulated expression of Cx40 and Cx43. The changes in Cx40 and Cx43 induced by Ang II were abolished by CNP through upregulation of phosphorylated AMP‑activated kinase a1 (AMPK) and downregulation of TGF‑β1. The effects of CNP on AMPK and TGF‑β1 levels were inhibited by KT5823 and pertussis toxin, inhibitors of protein kinase G (PKG) and NP receptor type C (NPR‑C), respectively. Thus, CNP can prevent Ang II‑induced dysregulation of Cx40 and Cx43 through activation of AMPK via the CNP‑PKG and CNP‑NPR‑C pathways in isolated beating rat atria. The present findings suggested that CNP may be therapeutically useful for clinical conditions involving cardiac dysregulation of Cx expression‑related diseases.
View Figures
View References

Related Articles

Journal Cover

December-2019
Volume 20 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ding DZ, Jia YN, Zhang B, Guan CM, Zhou S, Li X and Cui X: C‑type natriuretic peptide prevents angiotensin II‑induced atrial connexin 40 and 43 dysregulation by activating AMP‑activated kinase signaling. Mol Med Rep 20: 5091-5099, 2019
APA
Ding, D., Jia, Y., Zhang, B., Guan, C., Zhou, S., Li, X., & Cui, X. (2019). C‑type natriuretic peptide prevents angiotensin II‑induced atrial connexin 40 and 43 dysregulation by activating AMP‑activated kinase signaling. Molecular Medicine Reports, 20, 5091-5099. https://doi.org/10.3892/mmr.2019.10744
MLA
Ding, D., Jia, Y., Zhang, B., Guan, C., Zhou, S., Li, X., Cui, X."C‑type natriuretic peptide prevents angiotensin II‑induced atrial connexin 40 and 43 dysregulation by activating AMP‑activated kinase signaling". Molecular Medicine Reports 20.6 (2019): 5091-5099.
Chicago
Ding, D., Jia, Y., Zhang, B., Guan, C., Zhou, S., Li, X., Cui, X."C‑type natriuretic peptide prevents angiotensin II‑induced atrial connexin 40 and 43 dysregulation by activating AMP‑activated kinase signaling". Molecular Medicine Reports 20, no. 6 (2019): 5091-5099. https://doi.org/10.3892/mmr.2019.10744